Introduction
Femorofemoral crossover is an extra-anatomical arterial bypass which is usually performed in patients with ischaemic rest pain or tissue necrosis (ulceration and/or gangrene) caused by unilateral iliac artery occlusion. In these patients it is an accepted technique of limb salvage and avoids a major lower limb amputation. In patients with disabling claudication caused by iliac artery disease an aortofemoral or iliofemoral bypass is preferred by many surgeons rather than a femorofemoral crossover because of a high perceived complication rate associated with the latter procedure. It is claimed that these complications include a high perioperative mortalit~ groin sepsis and graft infection, false aneurysm formation and poor long term patency) These complications may lead to graft failure with return of symptoms and possibly limb loss secondary to graft infection. In addition further arterial surgery may be required to bypass progressive disease in the inflow and outflow arteries of the crossover graft.
Since 1969, at the Royal Adelaide Hospital, we have managed patients with disabling claudication and unilateral iliac artery disease by femorofemoral crossover graft rather than aortofemoral or iliofemoral bypass. We believe that the complications of femorofemoral crossover grafts are overstated and femorofemoral crossover is a safer procedure than aortic or iliac surgery. This paper reports our experience and the results achieved by this policy. In particular we have examined perioperative complications and longterm follow-up in terms of graft patenc~ limb loss, patient survival and complications such as graft infection and false aneurysm formation.
Patients and Methods
Patients undergoing femorofemoral crossover grafts for disabling claudication during the 22 year period from 1971 to 1992 were identified from the Vascular Studies Unit databases. The case notes were reviewed and details of operation, follow-up and complications were recorded.
Statistical analysis
Success, failure and complications were analysed according to the guidelines of the Society of Vascular Surgery (SVS) and the International Society for Cardiovascular Surgery (ISCVS). 2 Primary graft patency was defined as uninterrupted graft patency and secondary patency as procedures performed on the graft or anastomoses to maintain or restore patency. Patency was computed using the Kaplan-Meier method of life table analysis. 3 Patients who died or were lost to follow-up were censored at their last follow-up visit. Discrete variables were analysed using the Chi-squared test and p-values of less than 0.05 were considered significant.
Results
During the 22 year period from 1971 to 1992, 427 patients underwent a femorofemoral crossover graft at the Royal Adelaide Hospital. Of these, 211 procedures were performed for disabling claudication and form the basis of this study. There were 175 males (83%) and 36 females (17%) with a group mean age of 68 years (range 36-99 years). Fifteen patients (7%) were diabetic. One hundred and seventy-three patients (82%) had stenosis or occlusion of the native iliac artery and 38 patients (18%) had occlusion of a previous vascular procedure (bypass, endarterectomy or angioplasty) ( Table 1 ). The inflow to the crossover graft was the native femoral artery in 174 patients (82%) and a patent graft in 37 patients (18%). Details of the inflow and outflow arteries are shown in Table 2 . The cumulative graft patencies, limb and patient survival are shown in Fig. 1 . There were no deaths in the first (Table 5) and the indication for these are shown in Table 6 . Thirty-seven outflow procedures were performed in 32 patients (Table 7) . Six patients underwent thrombectomy of an occluded crossover graft and 27 had a second crossover graft inserted. Of these, six were at the same site, five had a new inflow site, 10 had a new outflow site and six had both a new inflow and outflow site. Angiograms were available for review in 162 patients (77%). Of these 87 patients had a patent recipient superficial femoral artery and 75 had an occluded recipient superficial femoral artery. There were no significant differences in cumulative primary graft patency between these two groups (p = 0.103, df = 1, log rank).
Discussion
The first femorofemoral crossover graft was performed at the Royal Adelaide Hospital in 1969, and since then, haemodynamically significant unilateral iliac artery stenosis and occlusion has been managed by femorofemoral grafts. Our experience does not support the often quoted objections to the procedure namely a high incidence of groin sepsis, a higher perioperative mortality and poor long term patency. ~'4 Consequently we do not reserve the operation for patients with critical leg ischaemia or complications (infection or false aneurysm formation) associated with previous vascular surgery but use it as a primary treatment option in patients with disabling claudication caused by unilateral iliac artery disease. Good graft patency rates together with a low complication rate have been reported by others s-9 and make it a preferred alternative to aortofemoral bypass, which can have a high mortality in patients with cardiorespiratory disease. However these results must be treated with caution as this is a retrospective study and patients were not randomised to receiving a Dacron or PTFE graft.
In patients who require a graft directly onto the profunda femoris arter)~ we expose the profunda as far distally as required until a disease free, soft artery is found. In addition we use a vein collar on the profunda artery. Although we do not have any data to support this technique, it is interesting to note that there were no significant differences in primary graft patency in patients with a patent vs. occluded recipient superficial femoral artery. However angiograms were only available for 162 patients (77%).
The long term follow-up in this series (mean 3.5 years, range 0.5-13 years) has allowed an assessment for the subsequent need for an inflow procedure. Out of 41 subsequent inflow procedures, 20 were performed for occlusion Of the crossover graft and 13 were for donor steal in the presence of a patent crossover graft (Table 6 ). The cumulative need for an inflow procedure was 5% per year (mean 27 months after crossover graft, range 1-78 months). The primary patency at 5 years (72%) was increased by secondary procedures (thrombectomy and local revision) to 89%, which compares favourably with published reports of patency for aortofemoral grafts.
In summar3~ a policy of performing femorofemoral crossover grafts in patients with disabling claudication caused by unilateral iliac artery disease produces good long term patency and is associated with a low complication rates. It should be considered as an alternative to aortofemoral grafting in these patients.
